GINZA NOA CLINIC
Tokyo, Japan International Patient Support
Contact Us

Why Do Some Cell Cultures Fail?

Cell cultures can fail when contamination, too few viable starting cells, unsuitable nutrients or incubation conditions, incorrect seeding density, damaging handling, or cell aging prevent the cells from growing as intended. The right conditions depend on the cell type; one culture’s feeding schedule or passage limit cannot simply be applied to another. Ecacc handbook 5th edition.pdf

A clinical batch can also grow successfully but fail its release checks. That is a different problem from poor growth, and neither result tells you whether a treatment works for a particular disease. This guide covers human and other mammalian cell cultures, with additional safeguards for cells intended for patients.

Why Do Some Cell Cultures Fail?

General information only, not personal medical advice or a laboratory operating protocol.

What culture failure means

Cell culture means maintaining and growing cells outside the body in a suitable nutrient medium. Moving part of a culture into a fresh vessel is called a passage or subculture. Some research cultures can be expanded repeatedly over months, but this is not a promise about how quickly a patient’s cells will grow. Stc basics

Sign What it means
No growth Cells do not establish or multiply after collection or thawing. Failure to attach matters for attachment-dependent cells, not cells normally grown in suspension.
Slow or stalled growth The batch will not reach the needed number in a workable time.
Contamination Bacteria, fungi, or mycoplasma show up in testing, or they are suspected and cannot be ruled out.
Wrong or changed cells Identity checks fail, unwanted cells take over, or the cells show signs they are no longer suitable.
Failed release checks Even if the dish looks full, the batch does not meet the release criteria below and cannot be released.

In research, failure can invalidate an experiment or require a restart. In clinical manufacturing, it can delay or cancel a planned treatment. A batch that fails required release criteria should not be administered.

How contamination ruins a culture

Contamination can enter through starting material, reagents, equipment, or handling. Cloudiness or visible fungal growth can be warning signs, but a clear-looking culture is not proof that it is clean. Ecacc handbook 5th edition.pdf

Mycoplasma is particularly easy to miss. UNC Lineberger’s Tissue Culture Facility explains that these bacteria may alter growth and cell behavior without obvious signs and are not visible by routine light microscopy. Dedicated testing is needed to confirm contamination; ordinary cell-culture antibiotics are not a reliable safeguard. Mycoplasmacontam

The consequences can extend beyond a failed dish. In a 2018 U.S. investigation, the CDC reported infections in 12 patients who received unapproved cord blood-derived products. All were hospitalized; no deaths were reported as of December 14, 2018. Bacteria in unopened vials indicated contamination before distribution. This was one outbreak, not a general culture-failure rate, and the investigation did not identify a particular culture step as the cause. Mm6750a5.htm

The FDA also identifies processing-related cross-contamination and inadequate infectious-disease testing as risks of unapproved regenerative products. Its reported harms include infections, blindness, and tumor formation; these are risks of the products and their use, not all consequences of poor cell growth. Important patient and consumer information about regenerative medicine therapies

A weak starting sample

The starting count must distinguish living cells from dead ones. A large total count can still leave too few viable cells to establish a culture. ECACC’s protocols instruct users to count viable cells after recovery rather than rely only on the number supplied with the vial, then use the seeding density specified for that cell line. Ecacc handbook 5th edition.pdf

A small sample is not automatically inadequate. Holoclar, an EU-authorized treatment for adults with moderate to severe limbal stem cell deficiency caused by burns, starts with 1–2 mm² of healthy limbal tissue from the patient’s eye. The EMA describes same-day transfer to the manufacturer, laboratory expansion, freezing until surgery is confirmed, and growth on a fibrin membrane for implantation. That sample size belongs to this specific eye treatment, not to stem cell treatments generally. Holoclar

If too few suitable cells remain, ask whether another collection would change the treatment process, what went wrong with the first sample, and whether repeating it is medically appropriate.

Feeding and incubation conditions

Medium supplies nutrients and helps maintain the chemical environment. A formulation suitable for one cell type may not support another. Ecacc handbook 5th edition.pdf

  • Unsuitable medium or supplements. Check the formulation, preparation, storage history, and the requirements of the actual cells.
  • Inadequate feeding. Nutrient depletion and accumulated waste can make conditions unsuitable as the culture grows.
  • Incubator settings. Temperature and carbon dioxide requirements must match the cell type and medium’s buffering system. There is no single setting for every culture.
  • pH changes. In media containing phenol red, yellow indicates acidity and purple indicates alkalinity. The color is a clue to investigate, not a sterility test or a diagnosis of the cause.

These checks should be made against the cell-specific protocol, not against a generic recipe. Differentiation adds another requirement: growing enough cells is not the same as guiding them into the intended specialized cell type. Ecacc handbook 5th edition.pdf Stc basics

Crowding and splitting errors

For attachment-dependent cells, confluence describes how much of the growth surface is covered. Leaving cells too long before passage can lead to overcrowding and cell injury. Seeding too sparsely can also prevent a culture from establishing. The acceptable density depends on the cell line and growth system. Ecacc handbook 5th edition.pdf

What happened What to check
Growth stopped before passage Density records, time since the last passage, feeding history, and contamination results.
Cells failed to reattach after passage Whether attachment is expected for these cells, the culture surface, enzyme exposure and neutralization, and the viable seeding count.
Growth was poor after thawing Recovery conditions and the measured viable-cell count, not only the pre-freeze count.

One practical example in ECACC’s guidance is enzyme exposure during passage: prolonged trypsin exposure can damage cell-surface receptors, and failure to neutralize it can prevent reattachment. A poor result immediately after splitting therefore calls for a review of handling records, not an assumption that the donor’s cells are inherently unsuitable. Ecacc handbook 5th edition.pdf

Cell aging

Many finite cell lines eventually enter senescence: the cells remain alive but stop dividing. Other cell lines can keep proliferating, so cell aging is not a universal explanation for stalled growth. Passage number and population doublings also measure different things—the number of transfers versus the number of times the population has doubled. Neither supplies a universal clinical safety cutoff. Ecacc handbook 5th edition.pdf

Equipment and mix-ups

A problem with equipment, labeling, or culture identity can undermine a batch even when some cells still look healthy. Ask which cell processing centre handled the sample and whether its records connect the collection, culture, tests, and final container. Cell appearance alone cannot establish identity. Ecacc handbook 5th edition.pdf

Manufacturing failures are not merely theoretical. On November 13, 2018, the FDA announced action against StemGenex for marketing an unapproved cellular product and cited manufacturing deviations, including some that could lead to microbial contamination. This was a specific enforcement action, not a finding about all laboratories. Fda warns stemgenex biologic laboratories llc illegally marketing unapproved cellular product

Freezing and thawing need their own controls. ECACC recommends checking viability after recovery; the count before freezing does not establish how many living cells remain afterward. Ecacc handbook 5th edition.pdf

A full dish can still fail

For cells intended for patients, ask which release criteria apply to that product. FDA guidance for investigational somatic cell therapies recommends microbiological testing and assessments of identity, purity, viability, and potency—the product’s biological activity. A statement such as “the cells grew well” does not tell you which of those requirements was met. Download

The same guidance recommends microbiological testing of cell banks, in-process material, and the final product, as appropriate. Testing complements manufacturing controls; a negative result is not a guarantee that all risks have been excluded. Download

After a failed batch

First ask whether the laboratory means slow growth, a confirmed failed result, or an investigation still in progress. More culture time is not a general remedy: it does not make a contaminated or misidentified batch suitable for administration. Whether another manufacturing attempt, another collection, or a different care plan is appropriate depends on the failure and the clinical situation.

Keep product quality separate from treatment evidence. For example, the FDA approved Ryoncil, a donor bone marrow-derived mesenchymal stromal cell therapy, on December 18, 2024, for steroid-refractory acute graft-versus-host disease in children aged 2 months and older. That specific approval does not establish that other cell products work for unrelated conditions. Fda approves remestemcel l rknd steroid refractory acute graft versus host disease pediatric

In Japan, a service offered under the regenerative-medicine practice framework is distinct from a marketed regenerative medical product reviewed under the product-approval framework. A filed treatment plan is not, by itself, proof of clinical efficacy. 0003

What to ask the lab that grew your cells

If you are told only “your cells did not grow,” ask for a written explanation that distinguishes low starting viability, slow expansion, contamination, and a failed release result. These questions can make that conversation more useful:

  • Which batch and which test? Request the batch identifier, test name, sample date, result, and the criterion it failed.
  • Where did growth change? Ask whether the problem was present on arrival, appeared after thawing or passage, or was detected only in final testing.
  • What did the investigation find? Ask whether handling records, medium and reagent lots, incubator logs, and contamination testing point to a cause—or whether the cause remains unknown.
  • What happens next? Confirm what will happen to the failed material, whether a new attempt is justified, what additional collection risks or costs apply, and how the delay affects standard-care options.

Discuss the safety plan if growth is poor or contamination is found with the treating clinician. Ask for the explanation in language you can understand; do not try to interpret an isolated laboratory number as a treatment recommendation.

Questions about a failed batch or a planned collection?

Write down the exact cause, the release result, and the evidence for your diagnosis and route — then confirm the next step in writing before you decide.

Contact the patient support team

Bottom line

The useful answer is not simply “the cells failed.” It is which stage failed, what the test showed, and whether the cause is known. Check the viable starting count, culture conditions, handling history, contamination results, and product-specific release decision. The 2018 CDC outbreak involving 12 hospitalized patients shows why a healthy-looking preparation is not enough to establish safety. Mm6750a5.htm

Discuss a failed clinical batch and any proposed repeat collection with a qualified clinician. Check the evidence and current regulatory status for the exact product, diagnosis, and route of administration; successful culture alone does not establish treatment benefit.

References

  1. UKHSA Culture Collections / ECACC: Fundamental Techniques in Cell Culture, fifth edition, sections 5–7, 9–10 and 14.
  2. NIH: Stem Cell Basics.
  3. UNC Lineberger Tissue Culture Facility: Mycoplasma.
  4. CDC: Infections After Receipt of Bacterially Contaminated Umbilical Cord Blood-Derived Stem Cell Products, 2018.
  5. FDA: Important Patient and Consumer Information About Regenerative Medicine Therapies.
  6. EMA: Holoclar product overview.
  7. FDA: StemGenex enforcement announcement, November 13, 2018.
  8. FDA: Content and Review of Chemistry, Manufacturing, and Control Information for Human Somatic Cell Therapy Investigational New Drug Applications, 2008, section IV.
  9. FDA: Ryoncil approval for pediatric steroid-refractory acute graft-versus-host disease, December 18, 2024.
  10. PMDA: Regulatory framework for regenerative medical products in Japan.